Liquidia Technologies Inc (LQDA)vsViatris Inc (VTRS)
LQDA
Liquidia Technologies Inc
$44.40
-0.20%
HEALTHCARE · Cap: $4.03B
VTRS
Viatris Inc
$19.91
+4.96%
HEALTHCARE · Cap: $21.56B
Smart Verdict
WallStSmart Research — data-driven comparison
Viatris Inc generates 3168% more annual revenue ($14.74B vs $450.91M). LQDA leads profitability with a 30.7% profit margin vs -2.8%. LQDA earns a higher WallStSmart Score of 60/100 (C).
LQDA
Buy60
out of 100
Grade: C
VTRS
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LQDA.
Margin of Safety
-81.6%
Fair Value
$8.88
Current Price
$19.91
$11.03 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Strong operational efficiency at 49.8%
Revenue surging 1843.0% year-over-year
Every $100 of equity generates 28 in profit
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
0.0% earnings growth
Trading at 20.3x book value
Distress zone — elevated risk
4.9% revenue growth
Expensive relative to growth rate
ROE of -2.9% — below average capital efficiency
Earnings declined 70.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : LQDA
The strongest argument for LQDA centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 30.7% and operating margin at 49.8%. Revenue growth of 1843.0% demonstrates continued momentum.
Bull Case : VTRS
The strongest argument for VTRS centers on Price/Book.
Bear Case : LQDA
The primary concerns for LQDA are P/E Ratio, EPS Growth, Price/Book.
Bear Case : VTRS
The primary concerns for VTRS are Revenue Growth, PEG Ratio, Return on Equity.
Key Dynamics to Monitor
LQDA profiles as a growth stock while VTRS is a turnaround play — different risk/reward profiles.
VTRS carries more volatility with a beta of 0.86 — expect wider price swings.
LQDA is growing revenue faster at 1843.0% — sustainability is the question.
VTRS generates stronger free cash flow (329M), providing more financial flexibility.
Bottom Line
LQDA scores higher overall (60/100 vs 42/100), backed by strong 30.7% margins and 1843.0% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Liquidia Technologies Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and markets various products for the unmet needs of patients in the United States. The company is headquartered in Morrisville, North Carolina.
Viatris Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?